Pharm Exec16h
FDA Approves Novo Nordisk’s Ozempic to Reduce Kidney Disease in Patients with Type 2 Diabetes, Chronic Kidney Disease
Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...
Pharm Exec16h
ADRIATIC Trial Demonstrates Significant Survival Benefit in LS-SCLC, Potentially Shaping Future Treatment Standards
Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results ...
Pharm Exec16h
Roche Appoints Wafaa Mamilli as Chief Digital Technology Officer
Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.
Pharm Exec21h
How the Continuing Need for Pain Medication Impacts the Pharma Industry
Paul Howe, chief commercial officer at Protega Pharma, discusses recent rule changes and how the industry is impacted by them ...
Pharm Exec16h
Essen Health Care Selected to Test Medicare Dementia Care Model
Essen Health Care announced that it is participating in the Guiding an Improved Dementia Experience (GUIDE) Model, an ...
Pharm Exec21h
Treating Disruptive Symptom’s in Crohn’s Patients: Q&A with Mark Genovese, MD
Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...